Design: We performed an observational cross-sectional cohort analysis in untreated (n ¼ 47) and treated (n ¼ 17) HIV-1 patients with different rates of disease progression and n ¼ 14 healthy individuals.
Methods:
We evaluated the frequency, the proportion and the function of total and virus-specific HLA-G þ CD8 R T cells by tetramer or intracellular cytokine staining, followed by flow cytometric analysis. Cytokine secretion of sorted CD8 R T-cell subsets was evaluated by Luminex assays.
Results:
The proportion and the absolute frequency of HLA-G þ HIV-1-specific CD8 R T cells were directly associated with CD4 þ T-cell counts and inversely correlated with viral loads, whereas total or HLA-G-negative HIV-1-specific CD8 R T cells were not. In functional assays, HLA-G þ CD8 R T cells from HIV-1-negative individuals had higher abilities to produce the antiviral (C-C chemokine receptor type 5) ligands MIP-1b (macrophage inflammatory protein-1ß), MIP-1a and Rantes.
Conclusion: HLA-G
þ HIV-1-specific CD8
Introduction
A large number of studies suggest that natural HIV-1 disease progression in untreated patients can be modulated by T cell-mediated immune responses [1] [2] [3] . In individuals with progressive disease (PD), HIV-1-specific CD8 R T cells mostly consist of IFN-g secreting effectormemory cells and, although these immune responses can exert antiviral immune pressure and influence viral sequence evolution, they are not very effective in suppressing HIV-1 replication [4] . In persons with natural control of HIV-1 infection, HIV-1-specific CD8 R T cells have a more polyfunctional profile that includes a higher proportion of IFN-g/IL-2 cosecreting central-memory CD8 R T cells [5] . Cellular immune responses in persons receiving suppressive antiretroviral therapy seem to be enriched for HIV-1-specific CD8 R T cells with a stem cell memory phenotype [6] .
Surface expression of HLA-G, a nonclassical HLA class Ib molecule typically expressed on placental trophoblasts, denotes a subset of CD4 þ and CD8 þ T cells with immunoregulatory properties that do not express the Forkhead Box P3 transcription factor [7] . HLA-Gexpressing T cells have the ability to suppress T-cell proliferation and reduce bystander immune activation, most likely through direct interactions between HLA-G and the inhibitory HLA-G ligand LILRB1 [8, 9] . HLA-G þ CD4 þ T cells are reduced during untreated progressive HIV-1 infection and are inversely associated with levels of cellular immune activation, suggesting that these cells may have beneficial effects on HIV-1 disease outcome [9] . In the present study, we analyzed the expression of HLA-G 
Materials and methods

Patients
Samples from 27 patients with chronic progressive HIV-1 infection (median viral loads 39 200 HIV-1 RNA copies/ ml and CD4 þ T-cell count 505 cells/ml), 20 controllers (median viral loads 62.5 RNA copies/ml and CD4 þ Tcell count 829.5 cells/ml) and 17 antiretroviral therapytreated patients (median viral loads 50 RNA copies/ml and CD4 þ T-cell count 784.5 cells/ml) were used for this study. A total of 14 HIV-1-negative individuals were also recruited. All patients gave written informed consent, and the study was approved by the Institutional Review Board of Massachusetts General Hospital/Partners Healthcare.
Peptide-major histocompatibility complex (MHC) class I multimer complexes MHC class I multimers refolded with epitopic HIV-1 (n ¼ 6) or cytomegalovirus/Epstein-Barr virus (CMV/ EBV) (n ¼ 2) peptides were purchased from ProImmune (Oxford, UK). A list of all class I multimers included in this study is included in Table S1 , http://links.lww.com/ QAD/B11.
Flow cytometry
Cryopreserved blood mononuclear cells were stained with blue viability dye (Life Technologies, Carlsbad, California, USA; 4 8C for 20 min), followed by incubation with appropriately titrated peptide-MHC class I multimer complexes at room temperature for 20 min in Ca 2þ -free media as described [10] . Cells were then washed and stained with antibodies against CD3, CD8 R , CD4 þ and HLA-G at 4 8C for 20 min. For intracellular cytokine staining, cells were stimulated overnight with optimal CD8 R T-cell peptides in presence of brefeldin A. Cells were then stained with blue viability dye (Life Technologies; 4 8C for 20 min), followed by incubation with appropriately titrated antibodies against CD3, CD4
þ , CD8 R and HLA-G. After fixation and permeabilization for 20 min at 4 8C using a commercial kit (Caltag, Buckingham, UK), cells were stained intracellularly for IFN-g, TNF-a, MIP-1b and IL-2. Cells were acquired on a Fortessa flow cytometer (Becton Dickinson, Franklin Lakes, New Jersey, USA) and analyzed using FlowJo X (Tree Star, Ashland, Oregon, USA). Analysis and presentation of cell distributions were performed using Prism (version 6; Graph Pad, San Diego, California, USA) and SPICE version 5.32, downloaded from http://exon.niaid.nih.gov/spice/ (NIAID; Bethesda, Maryland, USA).
Cell sorting
Cryopreserved blood mononuclear cells were thawed, and CD3
þ T-cell isolation was performed using immunomagnetic enrichment (Miltenyi Biotech, Cologne, Germany). T cells were stained with blue viability dye (Life Technologies) at 4 8C for 20 min. Afterward, cells were stained with antibodies directed against CD3, CD8
þ , HLA-G, CD25 and CD127. The following T-cell populations were livesorted, after exclusion of CD25 þ CD127 À CD4 þ Tregs, using an Aria cell sorting device (Becton Dickinson):
Luminex assays
The sorted cell populations were stimulated in 96-well plates with anti-CD3 (plate-bound) and anti-CD28 (soluble) antibodies or were left unstimulated for 4 days. Afterward, cell supernatants were analyzed by Luminex assays (Millipore, Billerica, Massachusetts, USA) for the following cytokines: Eotaxin, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, IFN-a2, IL-10, IL-12p70, IFN-g, IL-13, IL-17a, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP10, monocyte chemoattractant protein 1, TNF-a, TNF-b and vascular endothelial growth factor.
Statistics
Data are plotted as means or medians, as indicated. Statistical significance was tested using Mann-Whitney U tests or paired Wilcoxon tests, as appropriate. Correlations have been tested using Spearman test.
Results
HLA-G is expressed on a small number of bulk CD8
R T cells [7] ; however, the expression of HLA-G on HIV-1-specific CD8 R T cells is unknown. To investigate this, we analyzed proportions of HLA-G-positive cells within 36 HIV-1-specific CD8 R T-cell populations targeting different cytotoxic T lymphocyte epitopes (Table S1) and 23 CMV/EBV-specific CD8 R T-cell populations in cohorts of untreated HIV-1 patients. The frequency of HLA-G þ HIV-1-specific cells within total CD8 R T cells was higher in persons with spontaneous control of HIV-1 infection (n ¼ 19) than in patients with PD (n ¼ 17) (Fig. 1a) . This was also true when the proportion of HLA-G þ CD8 R T cells within a given population of multimer þ HIV-1-specific CD8 R T cells was evaluated ( Figure S1A , http://links.lww.com/QAD/B11). No difference was found between the frequencies or the proportions of CMV/EBV-specific HLA-G-positive CD8 R T cells in these two study groups ( Fig. 1a and Figure S1A , http://links.lww.com/QAD/B11).
Moreover, the frequencies of total or HLA-G-negative HIV-1-specific CD8 R T cells were also not significantly different (Fig. 1a and Figure S1B , http://links.lww.com/ QAD/B11). Of interest, the frequencies, the relative proportions and the absolute numbers of HIV-1-specific HLA-G-expressing CD8 R T cells were positively associated with total CD4 þ T-cell counts and inversely with viral loads (Fig. 1b and Figure S1C , http:// links.lww.com/QAD/B11). There was no association between total or HLA-G-negative HIV-1-specific CD8 R T cells (Fig. 1b and Figure S1D , http://links.lww.com/ QAD/B11) or HLA-G-positive CMV/EBV-specific CD8 R T cells and CD4 þ T-cell counts or HIV-1 viral loads ( Figure S1E , http://links.lww.com/QAD/B11). Interestingly, quantitative differences of HLA-G þ HIV-1-specific CD8
R T cells between progressors and controllers were most obvious for immune responses restricted by protective HLA class I alleles (HLA-B57/ B27), but not detectable for responses restricted by HLA-A2 or HLA-B8 (Fig. 1c and Figure S2A , http:// links.lww.com/QAD/B11); however, this was not true for total or HLA-G-negative HIV-1-specific CD8 R T cells (Fig. 1c and Figure S2B , http://links.lww.com/ QAD/B11).
For comparative purposes, we analyzed the proportions of total HLA-G-positive CD8 R T cells in the two study cohorts. HIV-1-infected controller patients had significantly higher frequencies of HLA-G-expressing CD8 R T cells than progressors, whereas frequencies of total and HLA-G-negative CD8 R T cells were highest in progressors (Fig. 1d and Figures S3A-C , http:// links.lww.com/QAD/B11). Notably, the frequencies and the absolute counts of HLA-G-expressing CD8 R T cells were positively associated with total CD4 þ T-cell countsandinverselywithviralloads (Fig.1dand 
CD8
R T cells was analyzed in 14 HIV-1-negative individuals, using Luminex assays. For these studies, CD8
T cells) were sorted as controls. Cells were then stimulated for 4 days with anti-CD3/anti-CD28 antibodies. HLA-G þ CD8 R T cells produced higher levels of IL-10 and IL-2 than Tc1 cells (Fig. 2a) . Moreover, HLA-G-positive CD8 R T cells produced higher levels of the chemokines MIP-1a, MIP-1b and Rantes (Fig. 2a) , which can act as competitive entry inhibitors for R5-tropic HIV-1 isolates [11] . No difference was observed between the cytokine profiles of Th1 and HLA-G þ
CD4
þ T cells (data not shown). To extend these investigations, we analyzed secretion of IFN-g and IL-2 in HLA-G þ and HLA-G À CMV/EBV/influenzaspecific (CMV-specific, EBV-specific, Flu-specific) CD8 R T cells from HIV-1-negative donors as well as in HIV-1-specific CD8 R T cells from controller patients using intracellular cytokine staining after overnight stimulation with peptides spanning HIV-1 gag (Fig. 2b  and c) . These data confirmed that virus-specific HLA-G þ
CD8
R T cells produced more IL-2, consistent with a relative phenotypic enrichment for more immature CCR7 þ T-cell subsets ( Figure S4 , http://links.lww.-com/QAD/B11), whereas IFN-g secretion was higher in virus-specific HLA-G À cells compared with HLA-G þ CD8 R T cells (Fig. 2b and c) .
Discussion
A large number of studies [1] show that T cell-mediated immune responses can influence HIV-1 disease progression. However, a perplexing aspect in HIV-1 immunobiology is that large numbers of HIV-1-specific CD8 R T cells are encountered in almost all untreated HIV-1-infected patients, but do not represent a correlate of HIV-1 immune control [12] . This suggests that not all antigen-specific CD8 R T cells contribute to antiviral immune defense and that specific subpopulations of antigen-specific CD8 R T cells may have improved antiviral effector functions. In previous studies, 'polyfunctional' central-memory HIV-1-specific CD8 R T cells with increased antigen-specific secretion of IL-2, stronger proliferative activities and enhanced expression of the Th1 master transcription factor T-bet were found to be associated with HIV-1 immune control [13, 14] , but it is likely that alternative, as of yet unidentified subsets of antigen-specific T cells are also involved in HIV-1 immune defense. Here, we described a subset of HIV-1-specific CD8
R T cells expressing HLA-G that is associated with immune control in untreated HIV-1 patients, and at least in HIV-1-negative individuals, these cells are able to secrete higher levels of the chemokines MIP-1a, MIP-b and Rantes, the physiological ligands for CCR5 [11] . These cells may therefore be able to actively participate in antiviral immune defense by competitively blocking CCR5, the viral coreceptor used by the majority of circulating viruses. Future studies will be necessary to determine if enhanced secretion of these chemokines can also be detected in virus-specific HLA-G þ CD8 R T cells from HIV-1-infected patients and whether these cells indeed have increased functional abilities to restrict HIV-1 replication steps or kill HIV-1-infected cells through enhanced cytotoxic properties. Given the extreme rarity of HIV-1-specific HLA-G þ
CD8
R T cells, which in many cases include less than 0.01% of all CD8 R T cells, such a functional analysis will be technically challenging and will require large quantities of patient cells. Notably, prior studies suggested that HLA-G-positive T cells have elevated expression levels of lymphoid tissue homing markers [15] and for this reason may have higher abilities to penetrate lymph nodes and increase immune surveillance in this anatomical compartment. A closer examination of HLA-G þ CD8 R T cells in lymphoid tissues, specifically in germinal centers that may serve as hotspots for viral replication [16] , therefore also represents a highly informative future research perspective. Finally, it is noteworthy that HLA-G þ -expressing T cells also have immunosuppressive properties [8] , consistent with our observation of higher IL-10 secretion in this cell subset. Although IL-10 has been associated with immune dysfunction and accelerated immune exhaustion in prior studies [17] , it is also possible that elevated regulatory properties of HLA-G þ CD8 R T cells may improve HIV-1 disease progression by inhibition of immune overactivation [9] . An improved understanding of the complexity and heterogeneity of the CD8 R T cellmediated immune responses against HIV-1 may ultimately allow the development of improved immune interventions for HIV-1 treatment and prevention.
